Ultragenyx (RARE) shares soared 7.8% in the last trading session to close at $44.64. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.1% gain over the past four weeks. The stock rallied after the company, along with its partner Mereo BioPharma, announced new positive 14- month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (UX143) in patients with osteogenesis imperfecta (OI). The data showe ...